Robert J More
CIK 1207792 · last filed 2026-08-12
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
TYRA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
BOX 10820
JACKSON, WY 83001
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VIR | Director | 558,573 | $10.39 | $5.80M | -$3.44M | 21 | 2026-08-12 |
| TYRA | Director | 3,823,425 | $20.82 | $79.62M | -$2.75M | 8 | 2026-06-01 |
| Allakos Inc. (ALLK) Delisted | 2,101,401 | $0.33 | $691.6K | -$4.54M | 2 | 2021-03-05 | |
| Sienna Biopharmaceuticals, Inc. (SNNA) Delisted | Director | 255,942 | — | — | -$209.4K | 5 | 2019-06-03 |
| GKOS | Director | 5,000 | $175.62 | $878.1K | $90.0K | 1 | 2015-06-30 |
| Volcano Corp (VOLC) Delisted | 10%+ Owner | 2,663,166 | — | — | -$1.69M | 10 | 2008-07-18 |
| CADENCE PHARMACEUTICALS INC (CADX) Delisted | 10%+ Owner | 90,369 | — | — | $0 | 1 | 2008-02-22 |
| Orexigen Therapeutics, Inc. (OREX) Delisted | 10%+ Owner | 1,857 | — | — | $6.00M | 2 | 2007-11-29 |
| Paratek Pharmaceuticals, Inc. (NOVC) Delisted | 10%+ Owner | 73,575 | — | — | -$275.9K | 2 | 2007-06-06 |
Recent Filings · Page 2 of 6
52 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-10-20 | VIR | Other (J) | — | $0 | EDGAR |
| 2023-06-02 | TYRA | Grant (A) | — | $0 | EDGAR |
| 2023-05-24 | VIR | Grant (A) | +6,027 | $0 | EDGAR |
| 2022-06-15 | TYRA | Grant (A) | — | $0 | EDGAR |
| 2022-06-13 | VIR | Other (J) | — | $0 | EDGAR |
| 2022-05-25 | VIR | Grant (A) | +6,405 | $0 | EDGAR |
| 2021-09-17 | TYRA | Mixed | +3,967,367 | $2.50M | EDGAR |
| 2021-08-02 | VIR | Mixed | −9,999 | -$357.0K | EDGAR |
| 2021-07-19 | VIR | Sell (S) | −11,670 | -$415.0K | EDGAR |
| 2021-07-06 | VIR | Sell (S) | −11,670 | -$524.3K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.